Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim commences new Pradaxa trial

Boehringer Ingelheim commences new Pradaxa trial

21st August 2014

Boehringer Ingelheim has announced the commencement of a new clinical trial assessing its oral anticoagulant Pradaxa among patients with atrial fibrillation who have received a coronary stent.

The first patients have been enrolled in the new international phase III study, RE-DUAL PCI, which will evaluate the efficacy and safety of the dabigatran etexilate therapy in patients with non-valvular atrial fibrillation who have undergone a percutaneous coronary intervention with stent placement to widen blocked coronary arteries.

Up to 8,500 patients will be involved in the study, with the results intended to aid understanding of how to reduce blood clot risk and minimise bleeding risk in this patient population.

Cooperatively conducted with the Harvard Clinical Research Institute, the research comes as part of the wider RE-VOLUTION trial programme, which will include 15 clinical trials involving more than 60,000 patients in over 100 countries globally.

Professor Klaus Dugi, chief medical officer at Boehringer Ingelheim, said: "We look forward to the continuing enrollment of patients in RE-DUAL PCI and expect to have full results in 2017."

This comes after the firm launched Pradaxa in the UK for use in the treatment of deep vein thrombosis and pulmonary embolism last month.ADNFCR-8000103-ID-801743636-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.